Xu, Youwei http://orcid.org/0000-0001-8069-7511
Wu, Canrong
Cao, Xiaodan
Gu, Chunyin
Liu, Heng
Jiang, Mengting
Wang, Xiaoxi
Yuan, Qingning
Wu, Kai
Liu, Jia
Wang, Deyi
He, Xianqing
Wang, Xueping
Deng, Su-Jun http://orcid.org/0000-0001-9266-0644
Xu, H. Eric http://orcid.org/0000-0002-6829-8144
Yin, Wanchao http://orcid.org/0000-0002-6889-4907
Funding for this research was provided by:
Youth Innovation Promotion Association of the Chinese Academy of Sciences (2021278)
National Natural Science Foundation of China (32171189, 82122067, 81902085, 32130022)
Ministry of Science and Technology of the People's Republic of China (2018YFA0507002)
Article History
Received: 12 April 2022
Accepted: 6 May 2022
First Online: 31 May 2022
Competing interests
: H.E.X., W.Y., Y.X., C.W., H.L., M.J., X.X.W., Q.Y., and K.W. have declared no competing interest. S.-J.D., X.C., C.G., J.L., D.W., X.H., and X.P.W., are employees of Shanghai Jemincare Pharmaceuticals Co. Ltd., and are developing JMB2002 as a potential anti-Omicron therapeutic.